• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment.

Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment.

机构信息

Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.

出版信息

Support Care Cancer. 2013 Jan;21(1):245-51. doi: 10.1007/s00520-012-1517-5. Epub 2012 Jun 9.

DOI:10.1007/s00520-012-1517-5
PMID:22684150
Abstract

BACKGROUND

Studies have demonstrated that patients at low risk for febrile neutropenia (FN) complications can be treated safely and effectively at home. Information on patient preferences for outpatient treatment of this condition will help to optimize health care delivery to these patients. The purpose of this study was to elicit non-Hodgkin lymphoma patients' preferences on attributes related to outpatient treatment of FN.

METHODS

We used a self-administered discrete choice experiment questionnaire based on the attributes of out-of-pocket costs, unpaid caregiver time required daily, and probability of return to the hospital. Ten paired scenarios in which levels of the attributes were varied were presented to study patients. For each pair, patients indicated the scenario they preferred. Adjusted odds ratios (ORs) of accepting a scenario that described outpatient care for FN were estimated.

RESULTS

Eighty-eight patients completed the questionnaire. Adjusted ORs [95 % confidence intervals] of accepting outpatient care for FN were 0.84 [0.75, 0.95] for each $10 increase in out-of-pocket cost; 0.82 [0.68, 0.99] for each 1 h increase in daily unpaid caregiver time; and 0.53 [0.50, 0.57] for each 5 % increase in probability of return to the hospital.

CONCLUSIONS

Probability of return to the hospital was the most important attribute to patients when considering home-based care for FN. Patients considered out-of-pocket costs and unpaid caregiver time to be less important than probability of return to the hospital. This study identifies factors that could be incorporated into outpatient delivery systems for FN care to ensure adequate patient uptake and satisfaction with such programs.

摘要

背景

研究表明,患有发热性中性粒细胞减少症(FN)并发症低风险的患者可以安全有效地在家中接受治疗。了解患者对该疾病门诊治疗的偏好将有助于优化对这些患者的医疗服务。本研究旨在了解非霍奇金淋巴瘤患者对门诊治疗 FN 相关属性的偏好。

方法

我们使用了基于自付费用、每日非付费护理时间和返院概率的离散选择实验问卷对患者进行调查。向研究患者展示了 10 对具有不同属性水平的配对场景。对于每对场景,患者会选择他们更倾向的场景。然后对接受门诊 FN 治疗的场景的调整后优势比(OR)进行了估计。

结果

88 名患者完成了问卷。自付费用每增加 10 美元,接受 FN 门诊治疗的调整后 OR [95 %置信区间]为 0.84 [0.75, 0.95];每日非付费护理时间每增加 1 小时,调整后 OR [95 %置信区间]为 0.82 [0.68, 0.99];返院概率每增加 5 %,调整后 OR [95 %置信区间]为 0.53 [0.50, 0.57]。

结论

当考虑 FN 的家庭护理时,返院概率是患者最看重的属性。患者认为自付费用和非付费护理时间不如返院概率重要。本研究确定了可纳入 FN 门诊治疗的交付系统的因素,以确保患者充分接受并对这些项目感到满意。

相似文献

1
Eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment. eliciting patients' preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment.
Support Care Cancer. 2013 Jan;21(1):245-51. doi: 10.1007/s00520-012-1517-5. Epub 2012 Jun 9.
2
Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.老年乳腺癌、肺癌或非霍奇金淋巴瘤患者中性粒细胞减少相关发热的护理及相关费用。
Support Care Cancer. 2020 Jan;28(1):113-122. doi: 10.1007/s00520-019-04795-0. Epub 2019 Apr 15.
3
Health-related quality of life anticipated with different management strategies for febrile neutropenia in adult cancer patients.不同管理策略对成人癌症患者发热性中性粒细胞减少症相关健康相关生活质量的预期。
Support Care Cancer. 2012 Nov;20(11):2755-64. doi: 10.1007/s00520-012-1397-8. Epub 2012 Feb 17.
4
Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice.欧洲和澳大利亚临床实践中,非霍奇金淋巴瘤患者化疗引起的发热性中性粒细胞减少的经济成本。
BMC Cancer. 2012 Aug 22;12:362. doi: 10.1186/1471-2407-12-362.
5
A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.侵袭性非霍奇金淋巴瘤患者首次CHOP化疗后危及生命的中性粒细胞减少和发热性中性粒细胞减少的预测模型。
Leuk Lymphoma. 2000 Apr;37(3-4):351-60. doi: 10.3109/10428190009089435.
6
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.接受CHOP、CHOP-R或CNOP化疗治疗中危非霍奇金淋巴瘤患者发热性中性粒细胞减少症的住院风险及时机
Cancer. 2003 Dec 1;98(11):2402-9. doi: 10.1002/cncr.11827.
7
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.细胞毒性化疗后早期淋巴细胞减少作为发热性中性粒细胞减少的危险因素。
J Clin Oncol. 1996 Feb;14(2):636-43. doi: 10.1200/JCO.1996.14.2.636.
8
Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis.采用粒细胞集落刺激因子(GCSF)进行初级预防可降低接受 CHOP 化疗治疗的非霍奇金淋巴瘤(NHL)患者发生发热性中性粒细胞减少症的发生率,且不会对其生活质量产生不利影响:成本效益和生活质量分析。
Support Care Cancer. 2013 Mar;21(3):841-6. doi: 10.1007/s00520-012-1589-2. Epub 2012 Sep 13.
9
Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.发热性中性粒细胞减少症(FN)和培格非格司亭预防在接受高(> 20%)FN 风险化疗的乳腺癌和非霍奇金淋巴瘤患者中的应用:来自一项前瞻性观察性研究的结果。
Support Care Cancer. 2019 Apr;27(4):1449-1457. doi: 10.1007/s00520-018-4473-x. Epub 2018 Sep 26.
10
Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.年龄组对接受 R-CHOP 方案治疗弥漫性大 B 细胞淋巴瘤患者发热性中性粒细胞减少症风险评估和管理的影响。
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):297-305. doi: 10.1016/j.clml.2012.06.004.

引用本文的文献

1
A Systematic Review of Discrete Choice Experiments in Oncology Treatments.肿瘤治疗中离散选择实验的系统评价。
Patient. 2021 Nov;14(6):775-790. doi: 10.1007/s40271-021-00520-4. Epub 2021 May 5.
2
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.癌症合并低危中性粒细胞减少症脓毒症患者早期静脉转口服抗生素治疗(EASI-SWITCH 试验):一项随机对照试验的研究方案。
Trials. 2020 May 27;21(1):431. doi: 10.1186/s13063-020-04241-1.
3
What attributes should be included in a discrete choice experiment related to health technologies? A systematic literature review.

本文引用的文献

1
Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial.家庭治疗与住院治疗发热伴中性粒细胞减少症的成本比较:一项多中心随机试验分析。
J Clin Oncol. 2011 Oct 20;29(30):3984-9. doi: 10.1200/JCO.2011.35.1247. Epub 2011 Sep 19.
2
Evaluation of direct medical costs of hospitalization for febrile neutropenia.发热性中性粒细胞减少症住院直接医疗费用评估。
Cancer. 2010 Feb 1;116(3):742-8. doi: 10.1002/cncr.24773.
3
Methodological issues in the monetary valuation of benefits in healthcare.医疗保健中利益货币化的方法学问题。
与健康技术相关的离散选择实验应包含哪些属性?系统文献回顾。
PLoS One. 2019 Jul 18;14(7):e0219905. doi: 10.1371/journal.pone.0219905. eCollection 2019.
4
Discrete Choice Experiments in Health Economics: Past, Present and Future.健康经济学中的离散选择实验:过去、现在和未来。
Pharmacoeconomics. 2019 Feb;37(2):201-226. doi: 10.1007/s40273-018-0734-2.
5
A Comparative Study on Willingness to Pay for Breast Cancer and Osteoporosis Screening in Kerman, Southeastern Iran.伊朗东南部克尔曼地区乳腺癌和骨质疏松症筛查支付意愿的比较研究
Iran J Public Health. 2017 May;46(5):693-698.
6
Patient preferences for hospital quality: case study of iran.患者对医院质量的偏好:伊朗的案例研究
Iran Red Crescent Med J. 2013 Sep;15(9):804-8. doi: 10.5812/ircmj.12851. Epub 2013 Sep 1.
7
Risk as an attribute in discrete choice experiments: a systematic review of the literature.作为离散选择实验中一个属性的风险:文献的系统综述
Patient. 2014;7(2):151-70. doi: 10.1007/s40271-014-0048-1.
Expert Rev Pharmacoecon Outcomes Res. 2003 Dec;3(6):717-27. doi: 10.1586/14737167.3.6.717.
4
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.712例发热性中性粒细胞减少症患者门诊或住院治疗的结局与费用
J Clin Oncol. 2008 Feb 1;26(4):606-11. doi: 10.1200/JCO.2007.13.8222.
5
Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.使用癌症支持治疗多国协会(MASCC)风险指数管理实体瘤和淋巴瘤中的发热性中性粒细胞减少症:常规临床实践中的可行性和安全性
Support Care Cancer. 2008 May;16(5):485-91. doi: 10.1007/s00520-007-0334-8. Epub 2007 Sep 25.
6
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.评估化疗引起的发热性中性粒细胞减少症的总成本:一项针对社区肿瘤癌症患者的试点研究结果。
Oncologist. 2007 Apr;12(4):478-83. doi: 10.1634/theoncologist.12-4-478.
7
Patient preferences for managing asthma: results from a discrete choice experiment.患者对哮喘管理的偏好:离散选择实验的结果
Health Econ. 2007 Jul;16(7):703-17. doi: 10.1002/hec.1193.
8
Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.使用并发症预测评分对发热性中性粒细胞减少癌症患者进行门诊口服抗生素治疗。
J Clin Oncol. 2006 Sep 1;24(25):4129-34. doi: 10.1200/JCO.2005.03.9909.
9
The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone.低风险中性粒细胞减少发热患者的门诊管理:通过电话进行风险评估
Support Care Cancer. 2007 Mar;15(3):287-91. doi: 10.1007/s00520-006-0126-6. Epub 2006 Aug 29.
10
Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.低风险发热性中性粒细胞减少症癌症患者每日一次口服喹诺酮单药门诊治疗:基于经验证的风险预测规则对40例患者的初步研究
Cancer. 2006 Jun 1;106(11):2489-94. doi: 10.1002/cncr.21908.